Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥205.00 JPY
Change Today -11.00 / -5.09%
Volume 475.5K
4563 On Other Exchanges
As of 10:29 PM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

anges mg inc (4563) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/15 - ¥438.00
52 Week Low
08/25/15 - ¥186.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ANGES MG INC (4563)

Related News

No related news articles were found.

anges mg inc (4563) Related Businessweek News

No Related Businessweek News Found

anges mg inc (4563) Details

AnGes MG, Inc., a biopharmaceutical company, engages in the research and development of genetic medicines and medical devices. It markets Naglazyme, a drug for the treatment of mucopolysaccharidosis. The company is also primarily developing hepatocyte growth factor genetic medicine, Collategene, a gene medicine for the treatment of critical limb ischemia, which is a serious impairment of blood circulation in the legs, is in the last stage of clinical development. Its Collategene is indicated for the treatment of peripheral arterial diseases, ischemic heart diseases, Parkinson’s disease, and lymphedema. In addition, the company also develops NF-kB decoy oligonucleotide that includes atopic dermatitis, disc degeneration, and PTA balloon catheter; and cervical intraepithelial neoplasia and DNA therapeutic vaccines, as well as Allovectin, an immunotherapeutic vaccine. It has strategic alliances with BioLeaders Corporation for the development of CIN therapeutic vaccine; Hosokawa Micron Corporation for the technology development of poly lactic-co-glycolic acid particle preparations containing NF-kB decoy oligonucleotide; Medikit Co., Ltd. for the development and manufacture of percutaneous transluminal angioplasty medical device; Morishita Jintan Co., Ltd. for the research and development of healthcare products using Cure-Peptin; and Vical, Inc. for the development of Allovectin. The company was formerly known as MedGene Bioscience Co., Ltd. and changed its name to AnGes MG, Inc. in October 2001. AnGes MG, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.

47 Employees
Last Reported Date: 03/30/15
Founded in 1999

anges mg inc (4563) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

anges mg inc (4563) Key Developments

AnGes MG, Inc., Q2 2015 Earnings Call, Aug 04, 2015

AnGes MG, Inc., Q2 2015 Earnings Call, Aug 04, 2015

AnGes MG, Inc. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015; Provides Earnings Guidance for the Fiscal Year Ending Dec. 31, 2015

AnGes MG, Inc. reported unaudited consolidated earnings results for the six months ended June 30, 2015. Revenues were ¥240 million, compared to ¥174 million for the last year. Operating loss was ¥2,005 million, compared to ¥1,035 million for the last year. Net loss was ¥2,040 million, compared to ¥968 million for the last year. Net loss per share were ¥37.34 compared to ¥30.51 for the last year. Income before income taxes and minority interests was ¥2,033.5 million, compared to ¥964.07 million for the last year. Net cash used in operating activities was ¥2,000 million, compared to ¥839.84 million for the last year. Purchase of property, plant and equipment was ¥10.44 million, compared to ¥1.19 million for the last year. Purchase of intangible assets was ¥7.3 million, compared to ¥1.35 million for the last year. For the fiscal year ending Dec. 31, 2015, the company expected revenues of ¥450 million, operating loss of ¥5,800 million, ordinary loss of ¥5,800 million and net loss of ¥5,800 million or ¥108.32 per share.

AnGes MG, Inc. to Report Q2, 2015 Results on Aug 03, 2015

AnGes MG, Inc. announced that they will report Q2, 2015 results on Aug 03, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4563:JP ¥205.00 JPY -11.00

4563 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4563.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4563 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.7x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANGES MG INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at